Percentage of acute myeloid leukemia (AML) pathology reports that include FMS-like tyrosine 3-internal tandem duplication (FLT3-ITD) status. INSTRUCTIONS: This measure is to be reported each time an acute myeloid leukemia specimen pathology report is finalized during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. The results of FLT3-ITD testing of a specimen are frequently needed at some point during a patient's treatment. Pathologists are uniquely well positioned at the time of signing out the surgical pathology report to detail the disposition of FLT3-ITD testing for that specimen. Referring physicians depend on both the pathologists' interpretations of and any recommendations for tests in order to provide quality patient care. If the status is not indicated in each pathology report for the patient, unnecessary repeat testing may be performed delaying treatment and increasing cost. This measure monitors the success of pathologists in effectively communicating this important information for the purpose of care coordination and efficient use of resources.